King & Wood Mallesons has advised Pfizer Inc on its $295 million joint venture with Zhejiang Hisun Pharmaceutical Co Ltd, represented by Jun He. This is Pfizer's largest joint venture in China.

Hisun Pfizer Pharmaceutical Co Ltd is expected to manufacture and sell off-patent pharmaceutical products, including generic drugs, in China and the global market as well. The project is one of the first generic medicine projects that China is setting up jointly with multinationals, and also one of the largest pharmaceutical joint venture projects in the wealthy province of Zhejiang.

A team from King & Wood Mallesons’ China offices, led by partners Wang Kaiding, Zhang Xiaolian, Ning Xuanfeng and Xiao Jin, provided Pfizer legal services from deal structure to due diligence, and also antitrust review.

Liu Zhen is China senior journalist at ALB. Follow us on Twitter: @ALB_Magazine.

Other related stories are:

Related Articles

Appointments

Jun He hires partner in Shanghai

by Shangjing Li |

China’s Jun He Law Offices has boosted its employment law practice with the recent hire of Gordon (Minghao) Feng as a partner in the firm’s Shanghai office.

Deals

CC, Linklaters, Latham and JunHe on $7.7 bln Pirelli sale to ChemChina

by Shangjing Li, Reuters |

Clifford Chance, Linklaters and Latham & Watkins have scored key advisory roles on a $7.7 billion bid for Pirelli, the world’s fifth-largest tire maker, by a subsidiary of China National Chemical Corp (ChemChina).

Deals

North Asia Deals: Week of Dec. 21

by Karuna Jainpalli |

K&E, Latham, Skadden on Qihoo’s $9.3 bln take-private deal, Freshfields, Clifford Chance and Zhong Lun advise on sale of Nanyang Commercial Bank to Cinda, and more in this week’s North Asia Deals table.